Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation.
about
Fibroblast Growth Factor Signaling in Metabolic RegulationSite-Specific PEGylation of Therapeutic ProteinsInventing new medicines: The FGF21 storyFibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders.The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes.Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO miceTuning the Surface of Nanoparticles: Impact of Poly(2-ethyl-2-oxazoline) on Protein Adsorption in Serum and Cellular Uptake.Circulating FGF21 proteolytic processing mediated by fibroblast activation protein.Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis.Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases.Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.Bioanalytical approaches to assess the proteolytic stability of therapeutic fusion proteins.Towards the next generation of biomedicines by site-selective conjugation.Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus.Chronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action.Hydrodynamic delivery of FGF21 gene alleviates obesity and fatty liver in mice fed a high-fat diet.Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action.Responsive polymers for biosensing and protein deliveryGrowing polymers from peptides and proteins: a biomedical perspective
P2860
Q26772751-42BFA1E2-B53D-4E1C-B1E2-7F15F9324017Q26777819-C6DC77F1-D366-46E1-9048-1B4F252C3CD1Q26823319-F9C77671-7631-4F5F-8EEE-82CF1C971B89Q27686803-47D001EB-33CE-45D9-AA9D-7AD32D65A0A8Q30234616-F9D24DE8-C209-4A96-B744-147E84172900Q33869232-350C855E-45AA-486F-8859-407CA862CFD8Q36046908-99084702-D897-4AF1-8CBE-645E14B71446Q36611366-3BA21A12-9942-4350-BF7C-039DAAB64A85Q36746670-3EC6BB1D-6558-4DB5-9F56-A9A7F068249FQ38201778-60A94CFA-151C-45C4-87EB-18E1B8C7E23FQ38633258-BD76CC08-0CEE-4D6B-9F52-77C8F65DBE44Q38652655-14B1CF4C-E2B4-4D10-A997-E7E4812E084DQ38706553-183F7050-E6F5-4DB3-80DA-77A188004A69Q38794405-24F98D38-03B0-463B-B919-FC10B3A92EBEQ42508659-DC05CA2B-E0EF-4FAD-9464-BF93D1E20CD4Q42870834-AA821D92-CEBB-4743-A79E-BFC9AC51A4B5Q52649955-8DA8BB39-8D10-455C-8055-37217915FCF8Q57365186-208BA047-2882-4308-B8A8-46BDED2856C8Q57367761-1F3D82FA-6CA3-4B31-B3EC-D3CF724B20EE
P2860
Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Polyethylene glycol modified F ...... nd minimize vacuole formation.
@en
Polyethylene glycol modified F ...... nd minimize vacuole formation.
@nl
type
label
Polyethylene glycol modified F ...... nd minimize vacuole formation.
@en
Polyethylene glycol modified F ...... nd minimize vacuole formation.
@nl
prefLabel
Polyethylene glycol modified F ...... nd minimize vacuole formation.
@en
Polyethylene glycol modified F ...... nd minimize vacuole formation.
@nl
P2093
P356
P1476
Polyethylene glycol modified F ...... nd minimize vacuole formation.
@en
P2093
Allen Sickmier
Ed Belouski
Jeanine Bussiere
Junming Yie
Kenneth W Walker
Shanaka Stanislaus
P304
P356
10.1021/BC300603K
P577
2013-05-09T00:00:00Z